Respiratory Medicine
Volume 105, Issue 1 , Pages 3-7 , January 2011

Omalizumab treatment and exercise capacity in severe asthmatics – Results from a pilot study

  • Christoph Schäper

      Affiliations

    • Department of Internal Medicine B – Cardiology, Intensive Care, Pulmonary Medicine and Infectious Diseases, Friedrich-Loeffler-Str. 23, D-17475 Greifswald, Germany
    • Corresponding Author InformationCorresponding author.
    • CS and SG contributed equally to this work.
    • ,
  • Sven Gläser

      Affiliations

    • Department of Internal Medicine B – Cardiology, Intensive Care, Pulmonary Medicine and Infectious Diseases, Friedrich-Loeffler-Str. 23, D-17475 Greifswald, Germany
    • Tel.: +49 38348622401; fax: +49 38348622422.
    • CS and SG contributed equally to this work.
    • ,
  • Stephan B. Felix

      Affiliations

    • Department of Internal Medicine B – Cardiology, Intensive Care, Pulmonary Medicine and Infectious Diseases, Friedrich-Loeffler-Str. 23, D-17475 Greifswald, Germany
    • ,
  • Annette Gogolka

      Affiliations

    • Institute for Allergy and Asthma Research Berlin, Tempelhofer Damm 176, D-10299 Berlin, Germany
    • ,
  • Beate Koch

      Affiliations

    • Department of Internal Medicine B – Cardiology, Intensive Care, Pulmonary Medicine and Infectious Diseases, Friedrich-Loeffler-Str. 23, D-17475 Greifswald, Germany
    • ,
  • Matthias Krüll

      Affiliations

    • Institute for Allergy and Asthma Research Berlin, Tempelhofer Damm 176, D-10299 Berlin, Germany
    • Department of Pneumology and Infectious Diseases, Charité, University Medicine Berlin, Germany
    • ,
  • Ralf Ewert

      Affiliations

    • Department of Internal Medicine B – Cardiology, Intensive Care, Pulmonary Medicine and Infectious Diseases, Friedrich-Loeffler-Str. 23, D-17475 Greifswald, Germany
    • ,
  • Oliver Noga

      Affiliations

    • Institute for Allergy and Asthma Research Berlin, Tempelhofer Damm 176, D-10299 Berlin, Germany
    • Department of Pneumology and Infectious Diseases, Charité, University Medicine Berlin, Germany

Received 17 June 2010 ,Accepted 28 July 2010.

References 

  1. Buhl R, Hanf G, Soler M, Bensch G, Wolfe J, Everhard F, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J. 2002 Nov;20(5):1088–1094
  2. Buhl R, Soler M, Matz J, Townley R, O’Brien J, Noga O, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J. 2002 Jul;20(1):73–78
  3. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184–190
  4. Busse WW. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med. 2001;164(8 Pt 2):S12–S17
  5. Soler M, Matz J, Townley R, Buhl R, O’Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254–261
  6. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59(7):709–717
  7. Holgate S, Smith N, Massanari M, Jimenez P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy. 2009;64(12):1728–1736
  8. Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe J, Rosseau S, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol. 2006;117(6):1493–1499
  9. Wasserman K, Hansen JE, Sue DY, Stringer WW, Whipp BJ. Principles of exercise testing and interpretation: including pathophysiology and clinical applications. 4th ed.. Lippincott Williams and Wilkins; 2004;
  10. Fell CD, Liu LX, Motika C, Kazerooni EA, Gross BH, Travis WD, et al. The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(5):402–407
  11. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. Exercise capacity deterioration in patients with COPD: longitudinal evaluation over 5 years. Chest. 2005;128(1):62–69
  12. Arena R, Myers J, Abella J, Peberdy MA, Bensimhon D, Chase P, et al. Development of a ventilatory classification system in patients with heart failure. Circulation. 2007;115(18):2410–2417
  13. Kleber FX, Vietzke G, Wernecke KD, Bauer U, Opitz C, Wensel R, et al. Impairment of ventilatory efficiency in heart failure: prognostic impact. Circulation. 2000;101(24):2803–2809
  14. Diaz O, Villafranca C, Ghezzo H, Borzone G, Leiva A, Milic-Emil J, et al. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J. 2000;16(2):269–275
  15. Vassaux C, Torre-Bouscoulet L, Zeineldine S, Cortopassi F, Paz-Diaz H, Celli BR, et al. Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD. Eur Respir J. 2008;32(5):1275–1282
  16. Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba FC, Richter K, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest. 2005;128(3):1168–1178
  17. Noga O, Hanf G, Kunkel G, Kleine-Tebbe J. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. Int Arch Allergy Immunol. 2008;146(1):66–70
  18. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–968
  19. Glaser S, Noga O, Koch B, Opitz CF, Schmidt B, Temmesfeld B, et al. Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis. Respir Med. 2009;103(2):317–324
  20. ATS/ACCP . Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167(2):211–277
  21. Palange P, Ward SA, Carlsen KH, Casaburi R, Gallagher CG, Gosselink R, et al. Recommendations on the use of exercise testing in clinical practice. Eur Respir J. 2007;29(1):185–209
  22. Koch B, Schaper C, Ittermann T, Spielhagen T, Dorr M, Volzke H, et al. Reference values for cardiopulmonary exercise testing in healthy volunteers: the SHIP study. Eur Respir J. 2009;33(2):389–397
  23. Gitt AK, Wasserman K, Kilkowski C, Kleemann T, Kilkowski A, Bangert M, et al. Exercise anaerobic threshold and ventilatory efficiency identify heart failure patients for high risk of early death. Circulation. 2002;106(24):3079–3084
  24. Glaser S, Opitz CF, Bauer U, Wensel R, Ewert R, Lange PE, et al. Assessment of symptoms and exercise capacity in cyanotic patients with congenital heart disease. Chest. 2004;125(2):368–376
  25. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med. 2003;167(4):544–549
  26. Miller WF, Johnson RL, Wu N. Relationships between fast vital capacity and various timed expiratory capacities. J Appl Physiol. 1959;14(2):157–163

PII: S0954-6111(10)00344-6

doi: 10.1016/j.rmed.2010.07.023

Respiratory Medicine
Volume 105, Issue 1 , Pages 3-7 , January 2011

Article Tools

* Image Usage & Resolution